STOCK TITAN

[6-K] Argo Blockchain plc American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Centessa Pharmaceuticals plc (CNTA) filed a Form 4 reporting the grant of an equity award to non-executive director Mathias Hukkelhoven. On 06/20/2025 the director received a share option covering 40,000 ordinary shares at an exercise price of $12.43 per share. The option vests in full on the earlier of the first anniversary of the grant or the company’s next annual shareholder meeting, contingent upon continued board service. The option expires on 06/20/2035. Following the grant, the reporting person beneficially owns 40,000 derivative securities (options) and no change was reported in non-derivative share ownership. Ordinary shares may be represented by ADSs on Nasdaq, each currently equal to one ordinary share.

The filing is a routine director compensation disclosure and does not indicate open-market buying or selling of CNTA shares. The transaction increases potential future dilution by less than 0.1% of the company’s outstanding shares, a level generally viewed as immaterial for valuation purposes.

Centessa Pharmaceuticals plc (CNTA) ha presentato un modulo Form 4 segnalando la concessione di un premio azionario al direttore non esecutivo Mathias Hukkelhoven. Il 20/06/2025 il direttore ha ricevuto un opzione su azioni che copre 40.000 azioni ordinarie al prezzo di esercizio di 12,43 $ per azione. L'opzione matura completamente al più presto tra il primo anniversario della concessione o la prossima assemblea annuale degli azionisti della società, a condizione che il servizio nel consiglio continui. L'opzione scade il 20/06/2035. Dopo la concessione, la persona segnalante detiene beneficiariamente 40.000 titoli derivati (opzioni) e non è stato riportato alcun cambiamento nella proprietà di azioni non derivate. Le azioni ordinarie possono essere rappresentate da ADS sul Nasdaq, ciascuna attualmente pari a una azione ordinaria.

La segnalazione è una normale comunicazione sulla remunerazione dei direttori e non indica acquisti o vendite sul mercato aperto delle azioni CNTA. La transazione aumenta la possibile diluizione futura di meno dello 0,1% delle azioni in circolazione della società, un livello generalmente considerato irrilevante ai fini della valutazione.

Centessa Pharmaceuticals plc (CNTA) presentó un Formulario 4 reportando la concesión de un premio de acciones al director no ejecutivo Mathias Hukkelhoven. El 20/06/2025 el director recibió una opción sobre 40,000 acciones ordinarias con un precio de ejercicio de $12.43 por acción. La opción se consolida por completo en la fecha que antes ocurra entre el primer aniversario de la concesión o la próxima junta anual de accionistas de la empresa, condicionado a la continuidad en el servicio en la junta. La opción expira el 20/06/2035. Tras la concesión, la persona que reporta posee beneficiosamente 40,000 valores derivados (opciones) y no se reportaron cambios en la propiedad de acciones no derivadas. Las acciones ordinarias pueden estar representadas por ADS en Nasdaq, cada uno actualmente equivalente a una acción ordinaria.

La presentación es una divulgación rutinaria de compensación de directores y no indica compras o ventas en el mercado abierto de acciones CNTA. La transacción incrementa la posible dilución futura en menos del 0.1% de las acciones en circulación de la empresa, un nivel generalmente considerado insignificante para propósitos de valoración.

Centessa Pharmaceuticals plc(CNTA)는 비상무 이사 Mathias Hukkelhoven에게 주식 보상을 부여했다는 내용을 담은 Form 4를 제출했습니다. 2025년 6월 20일, 이사는 40,000주의 보통주에 대한 주식 옵션을 주당 $12.43의 행사 가격으로 받았습니다. 이 옵션은 부여일로부터 1주년 또는 회사의 다음 연례 주주총회 중 더 빠른 시점에 전액 취득되며, 이사회 서비스 지속이 조건입니다. 옵션 만료일은 2035년 6월 20일입니다. 부여 이후, 보고자는 40,000개의 파생 증권(옵션)을 실질적으로 보유하고 있으며, 비파생 주식 보유에는 변동이 보고되지 않았습니다. 보통주는 현재 각각 1주 보통주와 동일한 Nasdaq의 ADS로 대표될 수 있습니다.

이번 제출은 이사 보수 공개의 일환으로 CNTA 주식의 공개 시장 매수 또는 매도를 의미하지 않습니다. 이 거래는 회사 발행 주식의 0.1% 미만의 잠재적 미래 희석을 증가시키며, 이는 평가 목적으로 일반적으로 중요하지 않은 수준으로 간주됩니다.

Centessa Pharmaceuticals plc (CNTA) a déposé un formulaire 4 signalant l'attribution d'une récompense en actions au directeur non exécutif Mathias Hukkelhoven. Le 20/06/2025, le directeur a reçu une option d'achat portant sur 40 000 actions ordinaires à un prix d'exercice de 12,43 $ par action. L'option devient entièrement acquise à la date la plus proche entre le premier anniversaire de l'attribution ou la prochaine assemblée annuelle des actionnaires de la société, sous réserve de la poursuite du service au conseil. L'option expire le 20/06/2035. Suite à cette attribution, la personne déclarant détient de manière bénéficiaire 40 000 titres dérivés (options) et aucun changement n'a été signalé dans la détention d'actions non dérivées. Les actions ordinaires peuvent être représentées par des ADS sur le Nasdaq, chacune équivalant actuellement à une action ordinaire.

Le dépôt constitue une divulgation de routine sur la rémunération des administrateurs et n'indique pas d'achats ou de ventes sur le marché ouvert d'actions CNTA. La transaction augmente la dilution potentielle future de moins de 0,1 % des actions en circulation de la société, un niveau généralement considéré comme négligeable aux fins de valorisation.

Centessa Pharmaceuticals plc (CNTA) hat ein Formular 4 eingereicht, in dem die Gewährung einer Aktienprämie an den nicht geschäftsführenden Direktor Mathias Hukkelhoven gemeldet wird. Am 20.06.2025 erhielt der Direktor eine Aktienoption über 40.000 Stammaktien zu einem Ausübungspreis von 12,43 $ pro Aktie. Die Option wird vollständig fällig am früheren Zeitpunkt des ersten Jahrestages der Gewährung oder der nächsten jährlichen Hauptversammlung des Unternehmens, vorausgesetzt, die Tätigkeit im Vorstand wird fortgesetzt. Die Option läuft am 20.06.2035 ab. Nach der Gewährung besitzt die meldende Person wirtschaftlich 40.000 derivative Wertpapiere (Optionen) und es wurde keine Änderung im Besitz nicht-derivativer Aktien gemeldet. Stammaktien können durch ADS an der Nasdaq vertreten sein, wobei jede derzeit einer Stammaktie entspricht.

Die Meldung ist eine routinemäßige Offenlegung der Vergütung von Direktoren und deutet nicht auf Käufe oder Verkäufe von CNTA-Aktien am offenen Markt hin. Die Transaktion erhöht die potenzielle zukünftige Verwässerung um weniger als 0,1 % der ausstehenden Aktien des Unternehmens, ein Niveau, das für Bewertungszwecke allgemein als unerheblich angesehen wird.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine director option grant; neutral governance impact.

This Form 4 documents a standard annual equity award to an independent director, aligning board incentives with shareholder value. The 40,000-share option represents a de minimis fraction of the float, carries a 10-year term, and vests within 12 months. No open-market transaction occurred, so there is no immediate signal on insider sentiment. From a governance standpoint, the grant follows typical U.K./U.S. biotech practice and does not raise compensation red flags. Investors should view the filing as administratively neutral with negligible dilution risk.

Centessa Pharmaceuticals plc (CNTA) ha presentato un modulo Form 4 segnalando la concessione di un premio azionario al direttore non esecutivo Mathias Hukkelhoven. Il 20/06/2025 il direttore ha ricevuto un opzione su azioni che copre 40.000 azioni ordinarie al prezzo di esercizio di 12,43 $ per azione. L'opzione matura completamente al più presto tra il primo anniversario della concessione o la prossima assemblea annuale degli azionisti della società, a condizione che il servizio nel consiglio continui. L'opzione scade il 20/06/2035. Dopo la concessione, la persona segnalante detiene beneficiariamente 40.000 titoli derivati (opzioni) e non è stato riportato alcun cambiamento nella proprietà di azioni non derivate. Le azioni ordinarie possono essere rappresentate da ADS sul Nasdaq, ciascuna attualmente pari a una azione ordinaria.

La segnalazione è una normale comunicazione sulla remunerazione dei direttori e non indica acquisti o vendite sul mercato aperto delle azioni CNTA. La transazione aumenta la possibile diluizione futura di meno dello 0,1% delle azioni in circolazione della società, un livello generalmente considerato irrilevante ai fini della valutazione.

Centessa Pharmaceuticals plc (CNTA) presentó un Formulario 4 reportando la concesión de un premio de acciones al director no ejecutivo Mathias Hukkelhoven. El 20/06/2025 el director recibió una opción sobre 40,000 acciones ordinarias con un precio de ejercicio de $12.43 por acción. La opción se consolida por completo en la fecha que antes ocurra entre el primer aniversario de la concesión o la próxima junta anual de accionistas de la empresa, condicionado a la continuidad en el servicio en la junta. La opción expira el 20/06/2035. Tras la concesión, la persona que reporta posee beneficiosamente 40,000 valores derivados (opciones) y no se reportaron cambios en la propiedad de acciones no derivadas. Las acciones ordinarias pueden estar representadas por ADS en Nasdaq, cada uno actualmente equivalente a una acción ordinaria.

La presentación es una divulgación rutinaria de compensación de directores y no indica compras o ventas en el mercado abierto de acciones CNTA. La transacción incrementa la posible dilución futura en menos del 0.1% de las acciones en circulación de la empresa, un nivel generalmente considerado insignificante para propósitos de valoración.

Centessa Pharmaceuticals plc(CNTA)는 비상무 이사 Mathias Hukkelhoven에게 주식 보상을 부여했다는 내용을 담은 Form 4를 제출했습니다. 2025년 6월 20일, 이사는 40,000주의 보통주에 대한 주식 옵션을 주당 $12.43의 행사 가격으로 받았습니다. 이 옵션은 부여일로부터 1주년 또는 회사의 다음 연례 주주총회 중 더 빠른 시점에 전액 취득되며, 이사회 서비스 지속이 조건입니다. 옵션 만료일은 2035년 6월 20일입니다. 부여 이후, 보고자는 40,000개의 파생 증권(옵션)을 실질적으로 보유하고 있으며, 비파생 주식 보유에는 변동이 보고되지 않았습니다. 보통주는 현재 각각 1주 보통주와 동일한 Nasdaq의 ADS로 대표될 수 있습니다.

이번 제출은 이사 보수 공개의 일환으로 CNTA 주식의 공개 시장 매수 또는 매도를 의미하지 않습니다. 이 거래는 회사 발행 주식의 0.1% 미만의 잠재적 미래 희석을 증가시키며, 이는 평가 목적으로 일반적으로 중요하지 않은 수준으로 간주됩니다.

Centessa Pharmaceuticals plc (CNTA) a déposé un formulaire 4 signalant l'attribution d'une récompense en actions au directeur non exécutif Mathias Hukkelhoven. Le 20/06/2025, le directeur a reçu une option d'achat portant sur 40 000 actions ordinaires à un prix d'exercice de 12,43 $ par action. L'option devient entièrement acquise à la date la plus proche entre le premier anniversaire de l'attribution ou la prochaine assemblée annuelle des actionnaires de la société, sous réserve de la poursuite du service au conseil. L'option expire le 20/06/2035. Suite à cette attribution, la personne déclarant détient de manière bénéficiaire 40 000 titres dérivés (options) et aucun changement n'a été signalé dans la détention d'actions non dérivées. Les actions ordinaires peuvent être représentées par des ADS sur le Nasdaq, chacune équivalant actuellement à une action ordinaire.

Le dépôt constitue une divulgation de routine sur la rémunération des administrateurs et n'indique pas d'achats ou de ventes sur le marché ouvert d'actions CNTA. La transaction augmente la dilution potentielle future de moins de 0,1 % des actions en circulation de la société, un niveau généralement considéré comme négligeable aux fins de valorisation.

Centessa Pharmaceuticals plc (CNTA) hat ein Formular 4 eingereicht, in dem die Gewährung einer Aktienprämie an den nicht geschäftsführenden Direktor Mathias Hukkelhoven gemeldet wird. Am 20.06.2025 erhielt der Direktor eine Aktienoption über 40.000 Stammaktien zu einem Ausübungspreis von 12,43 $ pro Aktie. Die Option wird vollständig fällig am früheren Zeitpunkt des ersten Jahrestages der Gewährung oder der nächsten jährlichen Hauptversammlung des Unternehmens, vorausgesetzt, die Tätigkeit im Vorstand wird fortgesetzt. Die Option läuft am 20.06.2035 ab. Nach der Gewährung besitzt die meldende Person wirtschaftlich 40.000 derivative Wertpapiere (Optionen) und es wurde keine Änderung im Besitz nicht-derivativer Aktien gemeldet. Stammaktien können durch ADS an der Nasdaq vertreten sein, wobei jede derzeit einer Stammaktie entspricht.

Die Meldung ist eine routinemäßige Offenlegung der Vergütung von Direktoren und deutet nicht auf Käufe oder Verkäufe von CNTA-Aktien am offenen Markt hin. Die Transaktion erhöht die potenzielle zukünftige Verwässerung um weniger als 0,1 % der ausstehenden Aktien des Unternehmens, ein Niveau, das für Bewertungszwecke allgemein als unerheblich angesehen wird.

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
 
FORM 6-K
 
_____________________
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the month of June, 2025
 
Commission File Number: 001-40816
 
_____________________
 
Argo Blockchain plc
(Translation of registrant’s name into English)
_____________________
 
Eastcastle House
27/28 Eastcastle Street
London W1W 8DH
England
(Address of principal executive office)
_____________________
 
Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F.
 
Form 20-F    Form 40-F
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
 
 
 
 
EXHIBIT INDEX
 
Exhibit No.
1
Description
Restructuring and Directorate Change dated 30 June 2025
 
 
Press Release
 
30 June 2025
 
Argo Blockchain plc
 
("Argo" or "the Company")
 
Proposed Restructuring and Directorate Change
 
Restructuring
 
Argo Blockchain plc (LSE: ARB; NASDAQ: ARBK) announces a proposed restructuring to resolve its short and medium term capital needs.
 
On 9 May 2025, the Company announced its results for the year ended 31 December 2024.  The reports and accounts noted that "a material uncertainty exists that may cast significant doubt on the group's and company's ability to continue as a going concern."
 
The Company has actively been exploring solutions to address its capital structure and liquidity position. Following a review of the available and deliverable options with its legal and financial advisors, Argo is now proposing to implement a restructuring through a restructuring plan to be sanctioned by the High Court of England and Wales or other court in England and Wales of competent jurisdiction ("Court") under Part 26A Companies Act 2006 ("Restructuring Plan").
 
Argo and Growler Mining, LLC n/k/a Growler Mining Tuscaloosa, LLC ("Growler") have entered into a restructuring plan support agreement under which Growler has agreed to provide a senior secured multi-draw term loan to Argo ("Loan") for the purposes of providing working capital to Argo and its subsidiaries and to assist Argo to implement a financial restructuring which the board has concluded is necessary to avoid an uncontrolled insolvency and liquidation of Argo and its subsidiaries ("Restructuring"). 
 
Key terms of the Restructuring Plan
 
Under the Restructuring Plan, it will be proposed that:
 
1. the Loan will, at Growler's election, be paid in full in cash or fully converted into newly issued common stock (or ordinary shares) in Argo on the Effective Date of the Restructuring Plan (as defined below);
 
2. subject to sanction by the Court of the Restructuring Plan, Growler will contribute crypto assets with a book value of US$25-30m to Argo Operating US LLC ("Argo US"), a wholly owned subsidiary of the Company, in exchange for all common stock or membership interests in Argo US, and, following that, Growler will contribute all of its equity or membership interests in Argo US to the Company in exchange for additional new equity in Argo;
 
3. Argo's bond holders (which collectively hold bonds with a face value of approximately $40 million in the aggregate) will receive new common stock in Argo in full and final satisfaction of their claims and in accordance with the terms of the Restructuring Plan;
 
4. following conversion of its Loan (if applicable), issue of shares in in Argo in exchange for its contribution of all equity or membership interests held in Argo US, and the exit capital to be provided to Argo upon the Effective Date of the Restructuring Plan in exchange for additional new equity in Argo (as set forth below), it is envisaged that Growler would be left with at least 80% of the issued shares of the Company, with the exact proportions to be determined by reference to the value of its Loan, the assets contributed, and the exit capital provided. It is envisaged that bond holders would be left with the remaining equity, with existing equity holders in Argo having their shares cancelled and extinguished on the Effective Date and entitled only to a compromise Restructuring Plan payment in a nominal amount based on their pro rata holdings of shares; and
 
5. on the Effective Date of the Restructuring Plan, Growler will provide additional cash funding to Argo (the "Exit Capital") in exchange for further new Argo equity to ensure that, among other things, all payments required under the Restructuring Plan are made; the Company is sufficiently capitalised for a company of its type, industry and size to move forwards; the Company has funding for go-forward working capital needs. 
 
The Restructuring Plan will likely result in the Company's admission to the Main Market being cancelled.  It is Argo's intention to maintain the Company's Nasdaq listing.
 
The Loan
 
The Loan will be a secured multi-term term loan facility in an amount up to $7,500,000, with amounts available to be drawn down against an approved budget. The Loan will be interest bearing at SOFR plus 6% per annum (with a minimum interest rate of 10% per annum), with a 1.5% commitment fee and a 1.5% exit fee. The Loan will be secured by an "all assets" fixed and floating charge in favour of Growler, which shall include, without limitation, the equity interests in the subsidiaries of the Company. At Growler's discretion, one or more of the subsidiaries of the Company are required to grant to Growler a first ranking lien over their assets and property in support of the Loan.  The purpose of the Loan is to fund Argo's operations until the Effective Date of the Restructuring Plan (as explained below) and to meet professional fees and other costs necessarily incurred to implement the Restructuring Plan. Growler may, at its election, convert the Loan into equity upon sanction and implementation of the Restructuring Plan.
 
Company Subsidiaries and Operating Expenses
 
All of Argo's subsidiaries' respective assets and properties including, without limitation, all mining machines, furniture, fixtures, and equipment wherever located including those located at properties owned by the subsidiaries, including, without limitation, the Baie-Comeau facility, or that are otherwise located at a hosting site in the United States shall remain wholly owned, directly or indirectly, by the Company.  All operating expenses and lender or vendor claims of the subsidiaries shall be paid in the ordinary course during the Restructuring Process out of the proceeds of the Loan and the Exit Capital, as the case may be, with all such expenses and payments to be made included in the approved budget. 
 
The Court process
 
The implementation of the Restructuring Plan will be subject to the approval of the Court and will include the following steps:
 
●          an initial explanation of the main terms of the Restructuring Plan and proposed meetings of creditors and members (or classes of either of them) ("Practice Statement Letter") will be sent to affected creditors and members;
 
●          an application will be made to Court to approve the composition of classes of creditors and, if appropriate, members and the convening of meetings of such persons to consider the Restructuring Plan, proposed in the Practice Statement Letter ("Convening Hearing");

●          meetings of creditors and if appropriate, members (or classes of them) will be convened in accordance with terms approved by the Court in the Convening Hearing. A detailed explanation of the terms of the Restructuring Plan will be sent to affected creditors and members with the notices convening meetings of them ("Explanatory Statement");
 
●          the meetings of creditors and, if appropriate, members, will seek the approval of the Restructuring Plan and will be deemed to have approved the Restructuring Plan if approved at such meetings by 75% by value of such creditors (and, if appropriate, members);
 
       the Court will then be asked to sanction the Restructuring Plan ("Sanction Hearing"). If the Restructuring Plan has not been approved by all meetings of creditors and, if appropriate, members, convened in accordance with the orders of the Court in the Convening Hearing, the Court may, in its discretion, still sanction the Restructuring Plan if satisfied that (a) the Restructuring Plan has been approved by at least one "in the money" class of creditors or members; and (b) any dissenting class is not worse off under the proposed plan than it would be in the relevant alternative ("Relevant Alternative"). The Explanatory Statement will contain a detailed analysis of the Relevant Alternative, but it is likely   to be formal insolvency of Argo (that is liquidation or administration), which will return far less to creditors of Argo than is believed to be the case under the Restructuring Plan, and nothing for members; and
 
●          shortly after the order of the Court in the Sanction Hearing ("Sanctions Order"), Argo will file the Sanctions Order at Companies House (the English companies registry) on which event the Restructuring Plan will be effective and bind all affected creditors and members ("Effective Date").
 
It is expected that the Restructuring Plan will be presented to the Court by 29 August 2025 and, if sanctioned by the Court, the Effective Date will be before 30 November 2025.
 
Takeover Code
 
The implementation of the Restructuring Plan will result in Growler acquiring interests in shares carrying more than 30% of the Company's voting rights.  Under the UK Takeover Code, Growler's acquisition would trigger an obligation on Growler to make a mandatory offer to the remaining shareholders in Argo.  The Restructuring Plan is, therefore, conditional upon the Takeover Panel agreeing to a waiver of the obligation under Rule 9 to make a mandatory offer, subject to independent shareholders approving that waiver. If shareholders do not approve the Restructuring Plan and a Rule 9 waiver, Argo intends to seek the sanction of the Restructuring Plan by the Court on the basis that shareholders would be no worse off under the Plan than the Relevant Alternative (see above).   In these circumstances, Argo also intends to apply to the Panel to request that the Panel permit a dispensation under section 2(c) of the Introduction of the UK Takeover Code from the obligation that would otherwise arise on Growler to make a mandatory offer under Rule 9 in order to facilitate the rescue of Argo which is in serious financial difficulty.
 
No assurance of definitive agreements
 
There can be no assurance that any definitive agreements for the Restructuring Plan will be signed or that the Restructuring Plan will be consummated. Should Argo be unsuccessful in completing the Restructuring Plan, it is likely that Argo will need to enter into a formal insolvency process.
 
Directorate Change
 
Matthew Shaw has resigned from his position as Chairman and Director of the Company with effect from 27 June 2025. The Board wishes to thank Mr. Shaw for his service and contribution to the Company during his tenure and wishes him well in his future endeavours.
 
The Company is pleased to announce the appointment of Maria Perrella, currently serving as a Non-Executive Director, as Chair of the Board with immediate effect.
 
Justin Nolan, Chief Executive Officer, said, "This transaction is the culmination of a months-long process designed to preserve Argo's operations and maximize value for Argo's stakeholders. The Restructuring Plan gives Argo a clear path forward with a significantly deleveraged balance sheet and a long-term strategic investor in Growler."
 
This announcement contains inside information.
 
For further information please contact:
 
 
Argo Blockchain
 
 
 
Investor Relations
 
 
ir@argoblockchain.com
 
 
Tennyson Securities
 
 
 
Corporate Broker
 
Peter Krens
 
 
+44 207 186 9030
 
 
Fortified Securities
 
 
 
 Joint Broker
 
Guy Wheatley, CFA
 
 
+44 7493 989014
 
guy.wheatley@fortifiedsecurities.com
 
 
Tancredi Intelligent Communication
 
UK & Europe Media Relations
 
 
  argoblock@tancredigroup.com
 
 
 About Argo:
 
Argo Blockchain plc is a dual-listed (LSE: ARB; NASDAQ: ARBK) blockchain technology company focused on large-scale cryptocurrency mining. With a mining facility in Quebec and offices in the US, Canada, and the UK, Argo's global, sustainable operations are predominantly powered by renewable energy. In 2021, Argo became the first climate positive cryptocurrency mining company, and a signatory to the Crypto Climate Accord. For more information, visit www.argoblockchain.com.
 
Forward looking statements
 
This announcement contains "forward-looking statements," which can be identified by words like "may," "will," "likely," "should," "expect," "anticipate," "future," "plan," "believe," "intend," "goal," "seek," "estimate," "project," "continue" and similar expressions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company's current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The information in this announcement about future plans and objectives of the Company are forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, market and other conditions, the principal risks and uncertainties listed in the risk factors set forth in our Annual Report and Financial Statements and Form 20-F for the year ended 31 December 2024.
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Date: 30 June, 2025
ARGO BLOCKCHAIN PLC
 
By: /s/ Jim MacCallum
Name: Jim MacCallum
Title: Chief Financial Officer
 
 
 

FAQ

How many Centessa (CNTA) shares are covered by the option granted on 06/20/2025?

40,000 ordinary shares (or equivalent ADSs) are covered by the option.

What is the exercise price of the director's newly granted option in the Form 4?

The option’s exercise price is $12.43 per share.

When will the CNTA director option vest?

It vests on the earlier of one year from grant or the next annual shareholder meeting, subject to continued board service.

Does the Form 4 show any open-market purchase or sale of CNTA shares?

No. The filing reports only an option grant; no shares were bought or sold in the market.

What is the expiration date of the 40,000-share option granted to Mathias Hukkelhoven?

The option expires on 06/20/2035.
Argo Blockchain Plc

NASDAQ:ARBK

ARBK Rankings

ARBK Latest News

ARBK Latest SEC Filings

ARBK Stock Data

25.32M
71.87M
0.11%
2.78%
2.62%
Capital Markets
Financial Services
Link
United Kingdom
London